CG Oncology, Inc.’s Quiet Period Set To End on March 5th (NASDAQ:CGON)

CG Oncology’s (NASDAQ:CGONGet Free Report) quiet period will expire on Tuesday, March 5th. CG Oncology had issued 20,000,000 shares in its initial public offering on January 25th. The total size of the offering was $380,000,000 based on an initial share price of $19.00. During CG Oncology’s quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Ratings Changes

A number of analysts have recently issued reports on CGON shares. The Goldman Sachs Group started coverage on CG Oncology in a report on Tuesday, February 20th. They set a “neutral” rating and a $42.00 target price for the company. HC Wainwright started coverage on CG Oncology in a report on Wednesday, February 14th. They set a “buy” rating and a $75.00 target price for the company. Cantor Fitzgerald started coverage on CG Oncology in a report on Tuesday, February 20th. They set an “overweight” rating and a $75.00 target price for the company. Finally, Morgan Stanley began coverage on CG Oncology in a report on Tuesday, February 20th. They set an “overweight” rating and a $55.00 target price for the company.

Check Out Our Latest Research Report on CG Oncology

CG Oncology Stock Performance

CG Oncology stock opened at $44.40 on Thursday. CG Oncology has a one year low of $28.55 and a one year high of $50.23.

Insider Buying and Selling

In other CG Oncology news, Director Hong Fang Song bought 263,157 shares of the business’s stock in a transaction on Monday, January 29th. The shares were bought at an average cost of $19.00 per share, with a total value of $4,999,983.00. Following the transaction, the director now directly owns 613,928 shares in the company, valued at approximately $11,664,632. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other CG Oncology news, major shareholder Decheng Capital Global Life Sc bought 400,000 shares of the business’s stock in a transaction on Monday, January 29th. The shares were bought at an average cost of $19.00 per share, with a total value of $7,600,000.00. Following the transaction, the insider now directly owns 400,000 shares in the company, valued at approximately $7,600,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hong Fang Song bought 263,157 shares of the business’s stock in a transaction on Monday, January 29th. The stock was acquired at an average cost of $19.00 per share, for a total transaction of $4,999,983.00. Following the completion of the transaction, the director now owns 613,928 shares in the company, valued at $11,664,632. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 666,472 shares of company stock valued at $12,662,968.

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.

Read More

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.